A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine

Current treatment outcome of patients with glioblastoma (GBM) remains poor. Following standard therapy, recurrence is universal with limited survival. Tumors from 173 GBM patients are analysed for somatic mutations to generate a personalized peptide vaccine targeting tumor-specific neoantigens. All patients were treated within the scope of an individual healing attempt. Among all vaccinated patients, including 70 treated prior to progression (primary) and 103 treated after progression (recurrent), the median overall survival from first diagnosis is 31.9 months (95% CI: 25.0-36.5). Adverse events are infrequent and are predominantly grade 1 or 2. A vaccine-induced immune response to at least one of the vaccinated peptides is detected in blood samples of 87 of 97 (90%) monitored patients. Vaccine-specific T-cell responses are durable in most patients. Significantly prolonged survival is observed for patients with multiple vaccine-induced T-cell responses (53 months) compared to those with no/low induced responses (27 months; P = 0.03). Altogether, our results highlight that the application of personalized neoantigen-targeting peptide vaccine is feasible and represents a promising potential treatment option for GBM patients.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2024-08-11
DOI
https://doi.org/10.1038/s41467-024-51315-8
Citations
43
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
10.34
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine

Martin Glas, Claus Garbe, Annick Desjardins, Magdalena Feldhahn et al.
43 citations
Nature Communications
Immunotherapy and Immune Responses
10.34
article

A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine

Martin Glas, Claus Garbe, Annick Desjardins, Magdalena Feldhahn, Pauline Latzer, Gerald Illerhaus, Michael Castro, Vincent W. Li, Uwe M. Martens, Johannes Harter, Patrick Y. Wen, David M. Parker, Bence Sipos, William W. Li, Dirk Hadaschik, Christian la Fougère, Sied Kebir, Deborah T. Blumenthal, Luisa Sánchez‐Lorenzo, Oliver Bartsch, Alexander Golf, Christian Seitz, Matthew Williams, Florian Battke, Till‐Karsten Hauser, Lars Zender, Saskia Biskup, Henry S. Friedman, Karsten Geletneky, David A. Reardon, David M. Ashley, Martin Schulze, Santosh Kesari, Alexandra Miller, Annekathrin Reinhardt, Máté Hídvégi, Armin Rabsteyn, Dirk Biskup, Christina Kyzirakos-Feger, FABIO MASSAITI IWAMOTO, Henning Zelba, Borong Shao, Ryan T. Merrell, Paula de Robles, Julian Wünsche, Natalia Pieper, Thomas Okech, Simone Kayser, D. Brooke, Elisabeth C. Neil
article en
43 citations

Abstract

Current treatment outcome of patients with glioblastoma (GBM) remains poor. Following standard therapy, recurrence is universal with limited survival. Tumors from 173 GBM patients are analysed for somatic mutations to generate a personalized peptide vaccine targeting tumor-specific neoantigens. All patients were treated within the scope of an individual healing attempt. Among all vaccinated patients, including 70 treated prior to progression (primary) and 103 treated after progression (recurrent), the median overall survival from first diagnosis is 31.9 months (95% CI: 25.0-36.5). Adverse events are infrequent and are predominantly grade 1 or 2. A vaccine-induced immune response to at least one of the vaccinated peptides is detected in blood samples of 87 of 97 (90%) monitored patients. Vaccine-specific T-cell responses are durable in most patients. Significantly prolonged survival is observed for patients with multiple vaccine-induced T-cell responses (53 months) compared to those with no/low induced responses (27 months; P = 0.03). Altogether, our results highlight that the application of personalized neoantigen-targeting peptide vaccine is feasible and represents a promising potential treatment option for GBM patients.

Nature CommunicationsVol. 15(1)
Institute of Molecular Biotechnology (AT), University of Minnesota (US), Harvard University (US), Tel Aviv University (IL), University of Calgary (CA), Heidelberg University (DE), Columbia University Irving Medical Center (US), Tel Aviv Sourasky Medical Center (IL), Angiogenesis Foundation (US), University Hospital Heidelberg (DE), Budapest University of Jewish Studies (HU), NYU Langone Health (US), Universitätsklinikum Tübingen (DE), Center for Personalized Cancer Treatment (NL), Klinikum Darmstadt (DE), Center for Neuro-Oncology (US), Saint John's Health Center (US), Praxis für Humangenetik Tübingen (DE), Hopp Children's Cancer Center Heidelberg (DE), Dana-Farber Cancer Institute (US), Essen University Hospital (DE), CeGaT (Germany) (DE), University Children's Hospital Tübingen (DE), Duke Medical Center (US), Clinica Universidad de Navarra (ES), Klinik und Poliklinik für Neurologie (DE), Diakonie-Klinikum Stuttgart (DE), Duke University Hospital (US), SLK-Kliniken Heilbronn (DE), Pediatric Brain Tumor Foundation (US), Klinikum Stuttgart (DE), NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Jewish Theological Seminary (US), Vanderbilt University Medical Center (US)
Good health and well-being
Openalex Percentile: Top 1%
Immunotherapy and Immune Responses
10.34
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.